Analyzing...
Loading company...
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹27,548 Cr revenue.
COGS 32.4%, employees 17.5%.
“zero to six months...two big respiratory launches...expect to be the sole generic in those for a substantial period of time”
“two products...could be one of the largest products for the company...ballpark in that top two or top three product type of a profile for revenue”
“quarterly revenue of INR 7,074 crore, which is flat Y o Y.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 13.8%▲ | 10.5% |
| ROCE | 17.9%▲ | 13.8% |
| Net Margin | 15.5%▲ | 8.7% |
| EBITDA Margin | 24.6%▲ | 16.0% |
| Debt To Equity | 0.00x▼ | 0.21x |
| Rev Growth 3yr | 8.8%▲ | 5.8% |
| EPS Growth 3yr | 27.9%▲ | 3.6% |
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹28,351 Cr +2.9% | ₹27,548 Cr +6.9% | ₹25,774 Cr +13.3% | ₹22,753 Cr +4.5% | ₹21,763 Cr +13.6% | ₹19,160 Cr +11.8% | ₹17,132 Cr +4.7% | ₹16,362 Cr |
| Other Income | ₹1,023 Cr +18.7% | ₹862 Cr +15.4% | ₹747 Cr +57.0% | ₹475 Cr +69.3% | ₹281 Cr +5.6% | ₹266 Cr -22.7% | ₹344 Cr -27.8% | ₹477 Cr |
| Total Income | ₹29,374 Cr +3.4% | ₹28,409 Cr +7.1% | ₹26,521 Cr +14.2% | ₹23,229 Cr +5.4% | ₹22,044 Cr +13.5% | ₹19,426 Cr +11.2% | ₹17,476 Cr +3.8% | ₹16,839 Cr |
| COGS | ₹9,489 Cr +6.3% | ₹8,929 Cr +1.2% | ₹8,820 Cr +6.9% | ₹8,252 Cr -2.9% | ₹8,496 Cr +15.6% | ₹7,352 Cr +22.7% | ₹5,991 Cr +3.6% | ₹5,784 Cr |
| ₹23,078 Cr +6.9% | ₹21,589 Cr +4.7% | ₹20,624 Cr +8.5% | ₹19,008 Cr +3.5% | ₹18,369 Cr +13.8% | ₹16,136 Cr +5.5% | ₹15,298 Cr +3.6% | ₹14,760 Cr | |
| Profit Before Tax | ₹6,021 Cr -11.7% | ₹6,821 Cr +19.6% | ₹5,702 Cr +41.2% | ₹4,038 Cr +15.6% | ₹3,493 Cr +6.2% | ₹3,290 Cr +51.0% | ₹2,178 Cr +4.8% | ₹2,079 Cr |
| Exceptional Items | (₹276 Cr) | ₹0.00 Cr +100.0% | (₹195 Cr) -6.8% | (₹182 Cr) -0.2% | (₹182 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
| ₹1,476 Cr -3.5% | ₹1,530 Cr -1.1% | ₹1,547 Cr +28.6% | ₹1,203 Cr +28.8% | ₹934 Cr +5.1% | ₹889 Cr +40.8% | ₹631 Cr +10.8% | ₹570 Cr | |
| Net Profit | ₹4,533 Cr -14.0% | ₹5,269 Cr +26.9% | ₹4,154 Cr +46.6% | ₹2,833 Cr +11.2% | ₹2,547 Cr +6.6% | ₹2,389 Cr +59.3% | ₹1,500 Cr +0.5% | ₹1,492 Cr |
| Profit (Owners) | ₹4,546 Cr -13.8% | ₹5,273 Cr +27.9% | ₹4,122 Cr +47.1% | ₹2,802 Cr +11.3% | ₹2,517 Cr +4.7% | ₹2,405 Cr +55.5% | ₹1,547 Cr +1.2% | ₹1,528 Cr |
| Minority Interest | (₹13 Cr) -293.4% | (₹3 Cr) ↓ Decline | ₹32 Cr +3.8% | ₹31 Cr +3.6% | ₹30 Cr ↑ Recovery | (₹16 Cr) +65.2% | (₹47 Cr) -33.3% | (₹35 Cr) |
| Other Comprehensive Income | ₹606 Cr +177.3% | ₹219 Cr ↑ Recovery | (₹121 Cr) ↓ Decline | ₹138 Cr -64.1% | ₹384 Cr +137.6% | ₹161 Cr ↑ Recovery | (₹129 Cr) +55.4% | (₹290 Cr) |
| EPS | ₹56.29 | ₹65.28 | ₹51.05 | ₹34.71 | ₹31.19 | ₹29.82 | ₹19.18 | ₹18.96 |
| Diluted Shares | ₹81 Cr | ₹81 Cr | ₹81 Cr | ₹81 Cr | ₹81 Cr | ₹81 Cr | ₹81 Cr | ₹81 Cr |
| Profit Or Loss Of Associates | (₹11 Cr) +48.1% | (₹22 Cr) | (₹2 Cr) +38.8% | (₹3 Cr) +79.7% | (₹13 Cr) -0.2% | (₹13 Cr) +73.1% | (₹47 Cr) -176.4% | (₹17 Cr) |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Cipla Limited has informed the Exchange regarding 'Grant Of Stock Options and Employee Stock Appreciation Rights'.
Cipla Limited has informed the Exchange about change in Management
Cipla Limited has informed the Exchange about USFDA inspection at Company s manufacturing facility in Verna, Goa, India
Cipla Limited has informed the Exchange about Schedule of meet
Cipla Limited has informed the Exchange about Schedule of meet
Cipla Limited has informed the Exchange regarding allotment of 17915 securities pursuant to ESOP/ESPS on May 14, 2026
Cipla Limited has informed the Exchange regarding grant of stock options and the employee stock appreciation rights .
Cipla Limited has informed the Exchange regarding Appointment of Ms Joshi Apte & Associates as Cost Auditors of the company w.e.f. April 01, 2026.
Cipla Limited has informed the Exchange regarding Appointment of Mr Sushrut Kulkarni as President & Global Chief Integrated Product Development of the company w.e.f. May 18, 2026.
Cipla Limited has informed the Exchange regarding Outcome of Board Meeting held on May 13, 2026.
Cipla Limited has informed the Exchange about Investor Presentation
Cipla Limited has informed the Exchange regarding a press release dated May 13, 2026.
Cipla Limited has informed the Exchange that Record date for the purpose of Dividend is 05-Jun-2026.
Cipla Limited has informed the Exchange that Board of Directors at its meeting held on May 13, 2026, recommended Final Dividend of Rs. 13 per equity share.
Cipla Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.